SecBot SecBot
8-K ·Filed May 7, 2026

FHTX

Foghorn Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001628280-26-031669
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming IND filings for CBP (FHT-171) and EP300 degraders in 2027 and Phase 1 efficacy data for FHD-909 as key catalysts. Cash runway into H1 2028 reduces near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.20
T+0 close · May 7, 2026 · via day close
Latest settled
+9.76%
T+60 · $4.61
Vs SPY
+5.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $4.20entry
  2. T+1 · 6mo ago +5.71%α +4.88% · $4.44
  3. T+5 · 6mo ago −0.71%α −2.22% · $4.17
  4. T+20 · 6mo ago −13.33%α −16.47% · $3.64
  5. T+60 · 4mo ago +9.76%α +5.93% · $4.61

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Foghorn Therapeutics reported Q1 2026 collaboration revenue of $3.3M (down from $6.0M YoY), net loss of $19.9M (vs $18.8M), and EPS of -$0.29 (vs consensus -$0.28, a slight miss). Cash stood at $183.6M, extended into H1 2028. Pipeline advances remain on track, with Phase 1 FHD-909 trial progressing and selective CBP/EP300 degraders approaching IND-enabling studies.

Key Financial Metrics

EPS
−$0.29
est −$0.28 · -3.6%
Revenue
$3.3M
Rating
miss

Key Facts

  • Collaboration revenue $3.3M for Q1 2026, down from $6.0M YoY due to timing of work under Lilly agreement
  • Net loss $19.9M vs $18.8M YoY; EPS -$0.29 vs -$0.30 YoY
  • Cash, cash equivalents and marketable securities $183.6M as of March 31, 2026, providing runway into H1 2028
  • FHD-909 Phase 1 dose-escalation trial on track; IND-enabling studies for CBP and EP300 degraders expected in 2026 with INDs in 2027
  • Selected preclinical data presented at AACR 2026 showing combination activity with anti-PD-1 and KRAS inhibitors

Financial Impact

No material financial impact; company remains pre-revenue with collaboration revenue variability

revenuenetLosseps

Risk Factors

  • Clinical trial delays or failures, particularly for FHD-909
  • Dependence on Lilly collaboration for revenue and development
  • Need for additional capital beyond 2028 runway

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-031669
Document: a2026mayfoghornirpresent.htm0001628280-26-031669
Document: fhtx-20260507.htm0001628280-26-031669
Document: 0001628280-26-031669-index-headers.html0001628280-26-031669
Document: 0001628280-26-031669-index.html0001628280-26-031669
Document: 0001628280-26-031669.txt0001628280-26-031669
8-K Data (Synthetic)0001628280-26-031669

Track record

9 reports on FHTX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +31.85% at T+5 after the Oct 1, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $1.81 Now $1.79 −0.83% settles Dec 15
  2. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $2.04 Now $1.79 −12.25% settles Dec 8
  3. Oct 5, 20266w ago 3 Neutral 2/10 Entry $1.97 to $2.12 Now $1.79 −9.14% ▲ +7.36% +10.26% vs SPY
  4. Oct 5, 20266w ago SC 13G/A Neutral 4/10 Entry $1.97 to $2.13 Now $1.79 −9.14% ▲ +8.12% +11.30% vs SPY
  5. Oct 1, 20266w ago 8-K Bearish 7/10 Entry $2.92 to $2.09 Now $1.79 +38.70% ▲ +28.42% +29.13% vs SPY
  6. Aug 6, 202614w ago 8-K Mixed 5/10 Entry $5.57 to $4.87 Now $1.79 −67.86% ▼ −12.57% −13.17% vs SPY
  7. May 7, 202627w ago 8-K Neutral 3/10 Viewing Entry $4.20 to $3.64 Now $1.79 −57.38% ▼ −13.33% −16.47% vs SPY
  8. Apr 21, 202629w ago Press Release Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
  9. Apr 21, 202629w ago 8-K Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026